Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
16 Jul, 2021 (Friday)

            
SINOFERT(297)
Analysis:
According to the positive profit alert of Sinofert (297), it is expected that there will be an increase of 35% to 55% in net profit attributable to owners of the Company for the six months ended 30 June 2021 as compared to that for the six months ended 30 June 2020, which implies that the net profit for the six months ended 30 June 2021 will be between RMB604.8 million and RMB694.4, almost matching or even exceeding the full year net profit of RMB644 million for FY2020. The Company steadily increases R&D investment, and as a result, the capability of commercialization of research results was significantly improved, and technology reserves continued to be strengthened. (I do not hold the above stock)
Strategy:
Buy-in Price: $1.38, Target Price: $1.52, Cut Loss Price: $1.30


INNOVENT BIO(1801)
Analysis:
The company is a leading domestic bio-innovative pharmaceutical company. Through independent research and development + cooperation, the introduction of two-wheel drive has created a rich pipeline covering major diseases such as tumor, metabolism, autoimmunity, and ophthalmology, involving monoclonal antibodies, double antibodies, fusion proteins, and small molecules , Cell therapy and other major drug forms. The company has achieved a layout in a number of popular targets, and is expected to occupy an advantageous position in the competition of tumor treatment in the future. The company currently enters the clinical stage of 24 varieties, of which 5 have been commercialized, 5 are in registered or critical clinical phases, and 14 are in different clinical stages. At the same time, the company has developed from R&D, clinical advancement, production to commercialization. The strength of the entire process of new drug development has been verified, and the innovative drug pipeline is expected to continue to deliver.
Strategy:
Buy-in Price: $85.00, Target Price: $102.00, Cut Loss Price: $71.00



BYD (1211.HK) - New Platform Is Introduced Again

Investment Summary

Sales Volume of Electric Vehicles Hit a Record High in June

According to data, BYD sold 51,015 vehicles in June, up 51% yoy and up 10% mom. Specifically, 41,366 new energy vehicles were sold, up 192% yoy and up 26% mom, and 9,649 traditional fuel vehicles were sold, down 50.6% yoy and down 28.5% mom. The sales volume of new energy vehicles hit the Company's record high, exceeding the sales volume of new energy vehicles of rivals Tesla and SGM-Wuling in China. Passenger vehicles and commercial vehicles made a contribution of 49,765 units and 1,250 units, respectively. In H1, the Company sold 246,700 vehicles accumulatively, up 55.5% yoy.

In terms of the sales volume of new energy passenger vehicles in June, the sales volume of EVs reached 20,016 units, up 102% yoy and up 7% mom, and that of HEVs reached 20,100 units, up 537% yoy and up 55% mom. Benefited from the whopping sales figures of DM-i models, HEVs have displayed an outstanding performance.

BYD's three new DM-i models (Qin PLUS DM-i, Song PLUS DM-i, and Tang DM-i) have been launched successively since March this year. They are equipped with the self-developed "DM-i super plug-in hybrid" system, which are highly competitive. In June, the total sales volume of the three new DM-i models was expected to be approximately 17,000 units, with the cumulative order exceeding 120,000 units. Limited by the bottleneck of the blade battery production capacity, the supply exceeded the demand for the products. The average delivery cycle took approximately three months. In H2, Qin Pro DMi, Song Pro DMi, and Han DMi will also be launched. As the blade battery production capacity increases, the sales volume of DM-i series models is expected to continue to grow.

In addition, as BYD's first e platform 3.0-based model, Dolphin will be launched in the third quarter. It targets younger customers, aiming to fully tap the entry-level electric vehicles and travel markets.

Semiconductor's Spin-off Listing Activates a New Round of Positive Feedback Mechanism for Capital and Company Value

Recently, BYD's proposal to spin off its semiconductor business and to list it on the A-share GEM has been accepted, officially opening the way for multiple businesses to obtain value revaluation through the capital market. We believe that with the acceleration of the neutralization strategy, the spin-off listing of other sectors such as blade batteries, commercial vehicles, and photovoltaic energy storage may be successively achieved in the future. The improvement in operational efficiency and value reshaping brought about by the spin-off will push up the Company's potential value. The Company is expected to fully benefit from the dividend of the positive feedback mechanism for capital and company value.

Investment Thesis

Therefore, although there are various challenges in the future, we believe that the Company is entering into a growth period with more stability and sustainability.

In terms of STOP valuation adopt, we give the original business (automobile, mobile phone, rechargeable battery and photovoltaic business) 138/84 HK$/per share, power battery business and semiconductor business from two assumptions of optimistic expectation and cautious expectation. 176/90 and 12/4.4 HK$/per share, the overall valuation is respectively 321/176 HK$/per share, implying 45% and -20% upside respectively. For comprehensive consideration, we given the target price of 248.5 HK$, corresponding to 2021/2022/2023 110/83/60x P/E, 7.6/7.0/6.3x P/B, Accumulate rating.

(Closing price as at 14 July)

Risk

Sales of NEVs is not as good as expected

New business risk

Slow-down of Hand-set components business

Financials

Click Here for PDF format...




Recommendation on 16-7-2021
RecommendationAccumulate
Price on Recommendation Date$ 221.000
Suggested purchase priceN/A
Target Price$ 248.500
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2021 Phillip Securities (HK) Ltd. All Rights Reserved.